ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $10.18, but opened at $9.78. ABIVAX Société Anonyme shares last traded at $9.70, with a volume of 911 shares trading hands.
Wall Street Analyst Weigh In
Separately, Laidlaw initiated coverage on shares of ABIVAX Société Anonyme in a report on Monday, July 29th. They set a "buy" rating and a $48.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $36.50.
Check Out Our Latest Stock Analysis on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Performance
The business has a 50 day simple moving average of $10.64 and a 200-day simple moving average of $12.19.
Hedge Funds Weigh In On ABIVAX Société Anonyme
A number of hedge funds have recently added to or reduced their stakes in ABVX. Walleye Capital LLC boosted its stake in shares of ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock worth $2,965,000 after buying an additional 80,807 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock worth $150,000 after buying an additional 5,900 shares during the last quarter. abrdn plc boosted its stake in shares of ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company's stock worth $3,645,000 after buying an additional 198,225 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company's stock worth $12,113,000 after buying an additional 131,414 shares during the last quarter. Finally, Kennedy Capital Management LLC boosted its stake in shares of ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock worth $1,718,000 after buying an additional 31,331 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.
About ABIVAX Société Anonyme
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Articles
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
